Ads
related to: pembrolizumab- Side Effects
Learn About Possible Side Effects
at the Official Patient Site.
- What Is KEYTRUDA?
Learn About What KEYTRUDA Is & How
It May Help Eligible Patients.
- Get Financial Help
Find Assistance and Payment
Information for Eligible Patients.
- Taking KEYTRUDA?
Learn What to Expect When
Taking KEYTRUDA.
- Clinical Trial Results
See Clinical Trial Results
at the Official Site.
- Treatment Options
Learn About Treatment
Options With KEYTRUDA.
- Side Effects
Search results
Anti-Cancer Drug Pembrolizumab: Frequently Used Alone Or With Other Treatments
Forbes· 1 day agoPembrolizumab, sold as Keytruda by Merck & Co., was one of the first inhibitors to hit the market. A...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 5 days agoPreliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive ...
What's Going On With Iovance Biotherapeutics Today? - Iovance Biotherapeutics (NASDAQ:IOVA)
Benzinga· 4 days agoOn Thursday, Iovance revealed updated clinical findings for lifileucel in conjunction with pembrolizumab as a treatment for frontline advanced melanoma, as well as implementation ...
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Benzinga via Yahoo Finance· 4 days agoThursday, Merus N.V. (NASDAQ:MRUS) announced the publication of an abstract regarding petosemtamab...
Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
Digital Journal· 6 days agoThe three abstract titles are: Abstract #TPS9616: INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment ...
Immunotherapy for stomach cancer: Types and effectiveness
Medical News Today· 5 days agoImmunotherapy may help shrink a tumor or slow the growth of cancer cells. People may have it in...
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
Benzinga· 3 hours agoHELSINKI, Finland, May 28, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American
ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody
Pharmaceutical Technology via Yahoo Finance· 4 days agoThe Phase II study is evaluating petosemtamab in combination with Merck & Co’s PD-1 inhibitor...
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
FOX 23 News Albany· 5 days agoNotable data include an oral presentation on biomarker analyses from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial (NCT02811861), which evaluated lenvatinib (LENVIMA®), the orally ...
From Robust Response to Rapid Resistance
MedPage Today· 4 days agoThe cancer treatment landscape dramatically changed since the first approval of an immune checkpoint inhibitor (ICI), ipilimumab, a CTLA-4 inhibitor, in...
Ads
related to: pembrolizumab
